62. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, et al. (2003) Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 52: 2805–2813. 63. Naito Y, Takagi T, Oya-Ito T, Okada H, Suzuki T, et al. (2009) Impaired gastric ulcer healing in diabetic mice: role of methylglyoxal. J Physiol Pharmacol 60 Suppl 7: 123–130. 64. Luo B, Soesanto Y, McClain DA (2008) Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol 28: 651–657. 65. Devi MS, Sudhakaran PR (2011) Differential modulation of angiogenesis by advanced glycation end products. Exp Biol Med (Maywood) 236: 52–61. 66. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, et al. (2007) Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 101: 948–956. 67. Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, et al. (2011) Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta. Blood 118: 2015–2026. 68. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, et al. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465: 487–491. 69. Smadja DM, Bieche I, Helley D, Laurendeau I, Simonin G, et al. (2007) Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6). J Cell Mol Med 11: 1149–1161. 70. Zhang H, He Y, Dai S, Xu Z, Luo Y, et al. (2008) AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Invest 118: 3904–3916. 71. Kuczynski EA, Patten SG, Coomber BL (2011) VEGFR2 Expression and TGF- beta Signaling in Initial and Recurrent High-Grade Human Glioma. Oncology 81: 126–134. 72. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, et al. (2003) Regulation of vascular endothelial growth factor receptor-2 activity by caveolin- 1 and plasma membrane cholesterol. Mol Biol Cell 14: 334–347. Autophagy of VEGFR2 Impairs Diabetic Angiogenesis 73. Jopling HM, Howell GJ, Gamper N, Ponnambalam S (2011) The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochem Biophys Res Commun 410: 170–176. 74. Ryter SW, Lee SJ, Smith A, Choi AM (2010) Autophagy in vascular disease. Proc Am Thorac Soc 7: 40–47. 75. Meijer AJ, Codogno P (2008) Autophagy: a sweet process in diabetes. Cell Metab 8: 275–276. 76. Gonzalez CD, Lee MS, Marchetti P, Pietropaolo M, Towns R, et al. (2011) The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 7: 2–11. 77. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S (2007) Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109: 4793–4802. 78. Ramakrishnan S, Nguyen TM, Subramanian IV, Kelekar A (2007) Autophagy and angiogenesis inhibition. Autophagy 3: 512–515. 79. Bansode RR, Ahmedna M, Svoboda KR, Losso JN (2011) Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide. Int J Biol Sci 7: 629–644. 80. Lee SJ, Kim HP, Jin Y, Choi AM, Ryter SW (2011) Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis. Autophagy 7: 829–839. 81. Rask-Madsen C, King GL (2008) More sugar, less blood vessels: another piece in the puzzle of increased cardiovascular risk in diabetes. Arterioscler Thromb Vasc Biol 28: 608–610. 82. Eichmann A, Simons M (2012) VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 24: 188–193. 83. Yamagishi SI, Maeda S, Matsui T, Ueda S, Fukami K, et al. (2011) Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 84. Mendez JD, Xie J, Aguilar-Hernandez M, Mendez-Valenzuela V (2010) Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem 341: 33–41. 85. Kim W, Hudson BI, Moser B, Guo J, Rong LL, et al. (2005) Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1043: 553–561. PLOS ONE | www.plosone.org 14 October 2012 | Volume 7 | Issue 10 | e46720